ArticleCancer research2009
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine.Frontiers in medicine · 2026Article
- Developing Vaccines in Pancreatic Adenocarcinoma: Trials and Tribulations.Current oncology (Toronto, Ont.) · 2024Review
- Molecular Chaperone Receptors: An Update.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond.International journal of molecular sciences · 2019Review
- Immunological Outcomes Mediated Upon Binding of Heat Shock Proteins to Scavenger Receptors SCARF1 and LOX-1, and Endocytosis by Mononuclear Phagocytes.Frontiers in immunology · 2019Review
- Heat Shock Proteins in Cancer Immunotherapy.Journal of oncology · 2019Review
- Molecular Chaperone Receptors.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Tumor-derived inducible heat-shock protein 70 (HSP70) is an essential component of anti-tumor immunity.Oncogene · 2015Article
- The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies.Molecular therapy. Nucleic acids · 2014Article
- Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.Nature biotechnology · 2012Article
- Polymer-mediated DNA vaccine delivery via bystander cells requires a proper balance between transfection efficiency and cytotoxicity.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Heat shock proteins: conditional mediators of inflammation in tumor immunity.Frontiers in immunology · 2012Article
- Heat shock proteins and cancer vaccines: developments in the past decade and chaperoning in the decade to come.Expert review of vaccines · 2011Review
- A viral strategy to ambush tumors.Nature medicine · 2011Article
- Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.Nature medicine · 2011Article
- Investigating receptors for extracellular heat shock proteins.Methods in molecular biology (Clifton, N.J.) · 2011Article
- Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.Molecular therapy : the journal of the American Society of Gene Therapy · 2011Article
- Heat shock protein 90 mediates efficient antigen cross presentation through the scavenger receptor expressed by endothelial cells-I.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 2 countries.
Funding
Abstract
We have a long-term interest in the connectivity between autoimmunity and tumor rejection. However, outside of the melanocyte/melanoma paradigm, little is known about whether autoimmune responses to normal tissue can induce rejection of tumors of the same histologic type. Here, we induced direct, pathogen-like cytotoxicity to the normal pancreas in association with the immune adjuvant heat shock protein 70. In sharp contrast to our studies with a similar approach for the treatment of prostate cancer, inflammatory killing of the normal pancreas induced a Th1-like, anti-self-response to pancreatic antigens, which was rapidly suppressed by a concomitant suppressive regulatory T cell (Treg) response. Interestingly, even when Treg cells were depleted, the Th1-like response was insufficient to induce significant ongoing autoimmunity. However, the Th1-like response to antigens expressed in the pancreas at the time of damage was sufficient to induce rejection of tumors expressing either a foreign (ova) antigen or fully syngeneic tumor antigens (on Panc02 tumor cells), provided that Treg were depleted before inflammatory killing of the normal pancreas. Taken together, these data indicate that profound differences exist between the immunoprotective mechanisms in place between different tissues (pancreas and prostate) in their response to pathogen-like damage. Moreover, they also show that, although multiple layers of immunologic safeguards are in place to prevent the development of severe autoimmune consequences in the pancreas (in contrast to the prostate), tumor rejection responses can still be decoupled from pathologic autoimmune responses in vivo, which may provide novel insights into the immunotherapeutic treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.